PT  - JOURNAL ARTICLE
AU  - Mallat, Jihad
AU  - Hamed, Fadi
AU  - Balkis, Maher
AU  - Mohamed, Mohamed A.
AU  - Mooty, Mohamad
AU  - Malik, Asim
AU  - Nusair, Ahmad
AU  - Bonilla, Maria-Fernanda
TI  - Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study
AID  - 10.1101/2020.04.27.20082180
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.27.20082180
4099  - http://medrxiv.org/content/early/2020/05/02/2020.04.27.20082180.short
4100  - http://medrxiv.org/content/early/2020/05/02/2020.04.27.20082180.full
AB  - Background There is conflicting data regarding the use of hydroxychloroquine (HCQ) in COVID-19 hospitalized patientsObjective To assess the efficacy of HCQ in increasing SARS-CoV-2 viral clearanceDesign Retrospective observational studySetting Cleveland Clinic Abu DhabiParticipants Hospitalized adult patients with confirmed SARS-CoV-2 infectionIntervention NoneMeasurements The primary outcome was the time from a confirmed positive nasopharyngeal swab to turn negative. A negative nasopharyngeal swab conversion was defined as a confirmed SARS-CoV-2 case followed by two negative results using RT-PCR assay with samples obtained 24 hours apartResults 34 confirmed COVID-19 patients were included. Nineteen (55.9%) patients presented with symptoms, and 14 (41.2%) had pneumonia. Only 21 (61.8%) patients received HCQ. The time to SARS-CoV-2 negativity nasopharyngeal test was significantly longer in patients who received HCQ compared to those who did not receive HCQ (17 [13–21] vs. 10 [4–13] days, p=0.023). HCQ was independently associated with time to negativity test after adjustment for potential confounders (symptoms, pneumonia or oxygen therapy) in multivariable linear regression analysis. On day 14, 47.8% (14/23) patients tested negative in the HCQ group compared to 90.9% (10/11) patients who did not receive HCQ (p=0.016).Limitations Small sample size and retrospective design with a potential risk of selection biasConclusion HCQ was associated with a slower viral clearance in COVID-19 patients with mild to moderate disease. Data from ongoing randomized clinical trials with HCQ should provide a definitive answer regarding the efficacy and safety of this treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymized datasets can be made available on reasonable request after approval of our Ethics Committee.